title: Contrary effects of sphingosine-1-phosphate on expression of α-smooth muscle actin in transforming growth factor β1-stimulated lung fibroblasts.
abstract: Transforming growth factor-β1 (TGFβ1) plays a pivotal role in fibrosis in various organs including the lung. Following pulmonary injury, TGFβ1 stimulates conversion of fibroblasts to myofibroblasts that are mainly characterized by up-regulation of α-smooth muscle actin (αSMA) expression, and the resulting excess production of extracellular matrix proteins causes fibrosis with loss of alveolar function. The present study was undertaken to define the role of the sphingosine-1-phosphate (S1P) pathway in TGFβ1-induced expression of αSMA in human fetal lung fibroblasts, HFL1 cells. Analysis of mRNA revealed the existence of S1P(1), S1P(2), and S1P(3) receptor mRNAs. Treatment with TGFβ1 increased sphingosine kinase (SphK) activity and S1P(3) receptor mRNA at 24h after stimulation, and pharmacological data showed the involvement of sphingomyelinase, SphK, and S1P(3) receptor in the TGFβ1-induced up-regulation of αSMA with and without serum. Treatment with pertussis toxin and S1P(1) receptor antagonist W146 enhanced αSMA expression by TGFβ1/serum, and S1P decreased and increased αSMA levels with and without serum, respectively. TGFβ1 increased cyclooxygenase-2 expression in a manner dependent on serum and the sphingomyelinase/SphK pathway, and the response was decreased by pertussis toxin. Prostaglandin E(2), formed by TGFβ1/serum stimulation, decreased the TGFβ1-induced expression of αSMA via EP prostanoid receptor. These data suggest that S1P formed by TGFβ1 stimulation has diverse effects on the expression of αSMA, inhibition via the S1P(1) receptor-mediated and serum-dependent expression of cyclooxygenase-2 and the resulting formation of prostaglandin E(2), and stimulation via the S1P(3) receptor in a serum-independent manner.
authors.affiliation: Department of Internal Medicine, Toho University School of Medicine, Sakura Hospital, Sakura City, Chiba 285-8741, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kawashima
authors.forename: Risa
authors.initials: R
authors.lastname: Yamazaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Matsuzawa
authors.forename: Erika
authors.initials: E
authors.lastname: Yamaura
authors.forename: Mamoru
authors.initials: M
authors.lastname: Takabatake
authors.forename: Sho
authors.initials: S
authors.lastname: Otake
authors.forename: Yuta
authors.initials: Y
authors.lastname: Ikawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Fujino
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Murayama
mesh_terms: D000199:Actins / Q000378:metabolism*; D016718:Arachidonic Acid / Q000378:metabolism; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008168:Lung / Q000166:cytology; D008246:Lysophospholipids / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000235:genetics; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology*
chemical_list: C541116:ACTA2 protein, human; D000199:Actins; D008246:Lysophospholipids; D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; D053773:Transforming Growth Factor beta1; C060506:sphingosine 1-phosphate; D016718:Arachidonic Acid; D000242:Cyclic AMP; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D015232:Dinoprostone; D013110:Sphingosine